Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal Antibody IMC-A12 Presented at ASCO
-- Fully human IgG1 monoclonal antibody is well tolerated -- Four of 11 evaluable patients with advanced solid tumors show stable disease
Last Update: 2:07 PM ET Jun 5, 2007
NEW YORK, Jun 05, 2007 (BUSINESS WIRE) -- First-in-human results for IMC-A12, a monoclonal antibody developed by ImClone Systems Incorporated (IMCL : ImClone Systems Inc
News , chart , profile , more
Last: 40.12+0.68+1.72%
3:31pm 06/06/2007
Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
IMCL40.12, +0.68, +1.7%) and targeted to IGF-1R (insulin-like growth factor type 1 receptor), were presented at the annual meeting of the American Society of Clinical Oncology in Chicago. The IGF-IR is expressed on the cell surface of must human cancers and transmits signals that lead to tumor cell growth and proliferation, and inhibition of programmed cell death. Aberrant expression of the IGF-IR has been implicated in tumorigenesis and the development of tumor resistance to chemotherapy, hormonal therapies, and targeted therapies. IMC-A12 was well tolerated and showed activity in patients with advanced solid tumors.
Like its marketed product ERBITUX(R) (cetuximab), the monoclonal antibodies in the ImClone pipeline are all type 1 immunoglobulin G (IgG1) antibodies. In vitro, IgG1 antibodies elicit antibody-dependent cellular cytotoxicity (ADCC), which can kill cancer cells and may contribute to their overall therapeutic effects. These novel antibodies target cell surface receptors in various signaling pathways known or believed to play important roles in the growth and proliferation of tumors or tumor vasculature. Specific targets include insulin-like growth factor-1 receptor (IGF-1R), vascular endothelial growth factor receptor-1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor alpha (PDGFR(alpha)), FMS-like tyrosine kinase 3 receptor (FLT3), fibroblast growth factor receptor 3 (FGFR3), among others.
"Our pipeline consists of a robust collection of IgG1 monoclonal antibodies targeted against cellular pathways that are emerging as critical drivers of cancer growth, proliferation, and survival," said Eric Rowinsky, M.D., Chief Medical Officer and Senior Vice President of ImClone Systems. "With ERBITUX as our cornerstone, we are uniquely positioned to drive the science that will lead to new therapies of major clinical impact. As for IMC-A12, this first-in-human study paves the way for a wide range of activity finding studies many of which will begin over the next several months in a broad range of tumor types."
"We are extremely excited by our extensive pipeline of novel antibodies," said Alexander J. Denner, Ph.D., Chairman of ImClone System's Executive Committee. "The depth of our pipeline will allow us the flexibility to evaluate the potential of these antibodies to improve current standards of care as well as in novel combinations that may define new therapies to improve patient care."
